Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer

C. H. A. Lee1, S. Wilkins1,3 ©, K. Oliva1, M. P. Staples2 and P. J. McMurrick1

1Cabrini Monash University Department of Surgery and 3Cabrini Institute, Cabrini Hospital, Malvern, and 3Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Correspondence to: Dr S. Wilkins, Cabrini Monash University Department of Surgery, Cabrini Hospital, 183 Wattletree Road, Malvern, Victoria 3144, Australia (e-mail: simonwilkins@cabrini.com.au)

Background: Lymph node yield (LNY) of 12 or more in resection of colorectal cancer is recommended in current international guidelines. Although a low LNY (less than 12) is associated with poorer outcome in some studies, its prognostic value is unclear in patients with early-stage colorectal or rectal cancer with a complete pathological response following neoadjuvant therapy. Lymph node ratio (LNR), which reflects the proportion of positive to total nodes obtained, may be more accurate in predicting outcome in stage III colorectal cancer. This study aimed to identify factors correlating with LNY and evaluate the prognostic role of LNY and LNR in colorectal cancer.

Methods: An observational study was performed on patients with colorectal cancer treated at three hospitals in Melbourne, Australia, from January 2010 to March 2016. Association of LNY and LNR with clinical variables was analysed using linear regression. Disease-free (DFS) and overall (OS) survival were investigated with Cox regression and Kaplan–Meier survival analyses.

Results: Some 1585 resections were analysed. Median follow-up was 27.1 (range 0.1–71) months. Median LNY was 16 (range 0–86), and was lower for rectal cancers, decreased with increasing age, and increased with increasing stage. High LNY (12 or more) was associated with better DFS in colorectal cancer. Subgroup analysis indicated that low LNY was associated with poorer DFS and OS in stage III colonic cancer, but had no effect on DFS and OS in rectal cancer (stages I–III). Higher LNR was predictive of poorer DFS and OS.

Conclusion: Low LNY (less than 12) was predictive of poor DFS in stage III colonic cancer, but was not a factor for stage I or II colonic disease or any rectal cancer. LNR was a predictive factor in DFS and OS in stage III colonic cancer, but influenced DFS only in rectal cancer.

Presented to the 2017 Royal Australasian College of Surgeons Annual Scientific Congress, Adelaide, South Australia, Australia, May 2017; published in abstract form as ANZ J Surg 2017; 87(Suppl S1): 22

Funding information
Let's Beat Bowel Cancer

Paper accepted 2 July 2018
Published online 8 August 2018 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.96

Introduction

Oncological resection of colorectal cancer involves removing the tumour with clear margins and harvesting of draining lymph nodes. Adequate lymph node harvest allows accurate staging and minimizes the risk of understaging nodal positive disease. The AJCC/UICC recommend a minimum of 12 lymph nodes should be identified in colorectal cancer specimens1–4. Although lymph node yield (LNY) has been used as a surrogate indicator of adequate surgical resection, a substantial proportion of resections (30–50 per cent) still fall into the low LNY category based on population studies5–7.

Low LNY has been associated with poorer survival outcome in stage II and III colorectal cancer7–10. A systematic review11 concluded that increased LNY was associated with improved survival in stage II–III colonic cancer. LNY was also shown in a large population study to be an independent prognostic factor in node-negative colorectal cancer irrespective of T category12. This study12 concluded that stage migration alone contributed to the observed survival difference. Despite a rise in median LNY over recent years, the

© 2018 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Table 1  Clinicopathological characteristics and treatment events of patients

|                                | No. of treatment episodes* (n = 1585) |
|--------------------------------|-------------------------------------|
| Lymph node yield†              | 17 (8.2)                            |
| Age (years)‡                   | 71.6 (22–100)                       |
| Sex ratio (M:F)                | 809:776                             |
| ASA grade (n = 1584)           |                                     |
| I                              | 329 (20.8)                          |
| II                             | 670 (42.3)                          |
| III                            | 522 (33.0)                          |
| IV                             | 63 (4.0)                            |
| Tumour location                |                                     |
| Colon                          | 1015 (64.0)                         |
| Rectum                         | 570 (36.0)                          |
| Tumour site in colon           |                                     |
| Caecum                         | 167 (10.5)                          |
| Ascending colon                | 208 (13.1)                          |
| Hepatic flexure                | 71 (4.5)                            |
| Transverse colon               | 149 (9.4)                           |
| Splenic flexure                | 54 (3.4)                            |
| Descending colon               | 37 (2.3)                            |
| Sigmoid colon                  | 255 (16.1)                          |
| Rectosigmoid                   | 74 (4.7)                            |
| Neoadjuvant therapy            |                                     |
| Yes                            | 241 (15.2)                          |
| No                             | 1344 (84.8)                         |
| Neoadjuvant type               |                                     |
| Short-course radiotherapy      | 30 of 241 (12.4)                    |
| Long-course CRT               | 211 of 241 (87.6)                   |
| Operative urgency              |                                     |
| Emergency                      | 33 (2.1)                            |
| Urgent                         | 85 (5.4)                            |
| Elective                       | 1467 (92.6)                         |
| Differentiation                | n = 1408                            |
| Undifferentiated               | 8 (0.6)                             |
| Poor                           | 276 (19.6)                          |
| Moderate                       | 1048 (74.4)                         |
| Well                           | 76 (5.4)                            |
| pAJCC                          |                                     |
| 0 (pCR)                       | 58 (3.7)                            |
| I                             | 517 (32.6)                          |
| II                            | 534 (33.7)                          |
| III                           | 476 (30.0)                          |
| pT category                    |                                     |
| 0                              | 62 (3.9)                            |
| 1                              | 302 (19.1)                          |
| 2                              | 313 (19.7)                          |
| 3                              | 784 (49.5)                          |
| 4                              | 124 (7.6)                           |
| Lymphovascular invasion        | n = 1546                            |
| Yes                            | 429 (27.7)                          |
| No                             | 1117 (72.3)                         |
| Positive CRM                   |                                     |
| Yes                            | 1568                                |
| Yes                            | 23 (1.5)                            |
| No                             | 973 (62.1)                          |
| n.r.                           | 572 (36.5)                          |

*With percentages in parentheses unless indicated otherwise; values are †mean(s.d.) and ‡median (range). CRT, chemoradiotherapy; pAJCC, pathological stage according to the AJCC; pCR, complete pathological response; CRM, circumferential resection margin; n.r., not recorded.

Table 2 Univariable analysis of factors affecting lymph node yield

| Factor                                | β coefficient |
|---------------------------------------|---------------|
| Age (continuous)                      | −0.07 (−0.11, −0.03) |
| Sex                                   |               |
| M                                     | 1.00 (reference) |
| F                                     | 1.24 (0.88, 1.58) |
| BMI                                   | 0.07 (−0.15, 0.00) |
| Tumour location                       |               |
| Colon                                 | 1.00 (reference) |
| Rectum                                | −2.16 (−2.98, −1.33) |
| Tumour site in colon                  |               |
| Caecum                                | 1.00 (reference) |
| Ascending colon                       | 0.36 (−1.06, 1.77) |
| Hepatic flexure                       | 3.42 (1.08, 5.76) |
| Transverse colon                      | 0.26 (−1.50, 2.02) |
| Splenic flexure                       | 0.37 (−3.20, 3.93) |
| Descending colon                      | −1.17 (−4.30, 1.96) |
| Sigmoid colon                         | −0.94 (−2.45, 0.56) |
| Neoadjuvant therapy                   |               |
| No                                    | 1.00 (reference) |
| Yes                                   | −3.22 (−4.32, −2.12) |
| Neoadjuvant therapy (rectal)          |               |
| No                                    | 1.00 (reference) |
| Yes                                   | −2.33 (−3.63, −1.02) |
| Neoadjuvant therapy type              |               |
| Short-course radiotherapy             | 1.00 (reference) |
| Long-course CRT                       | −7.52 (−10.58, −4.45) |
| Surgical entry                        |               |
| Laparoscopic                          | 1.00 (reference) |
| Open                                  | −1.19 (−2.19, −0.19) |
| Hybrid                                | −1.62 (−3.18, −0.06) |
| Conversion                            | −1.06 (−2.39, 0.27) |
| Robotic                               | −4.70 (−6.77, −2.63) |
| Operative urgency                     |               |
| Elective                              | 1.00 (reference) |
| Emergency                             | 2.36 (−0.77, 5.49) |
| Urgent                                | 4.47 (2.47, 6.48) |
| Rectal cancer location                |               |
| Upper                                 | 1.00 (reference) |
| Mid                                   | −0.41 (1.64, 0.83) |
| Lower                                 | −2.98 (−4.26, −1.71) |
| Differentiation                       |               |
| Well                                  | 1.00 (reference) |
| Moderate                              | 1.33 (−0.41, 3.08) |
| Poor                                  | 2.13 (0.18, 4.09) |
| Undifferentiated                      | −2.03 (−6.48, 2.41) |
| pAJCC                                 |               |
| 0                                     | 1.00 (reference) |
| I                                     | 3.13 (1.07, 5.19) |
| II                                    | 5.50 (3.46, 7.55) |
| III                                   | 6.30 (4.18, 8.42) |
| dMMR IHC                              |               |
| Normal                                | 1.00 (reference) |
| MMR proteins absent                  | 2.83 (0.88, 4.78) |
| AL procedure side                    |               |
| Right                                 | 1.00 (reference) |
| Rectal                                | −2.53 (−3.47, −1.59) |
| Left                                  | −2.45 (−3.34, −1.55) |
| Other*                                | 5.27 (2.49, 8.05) |

Values in parentheses are 95 per cent confidence intervals. *Includes subtotal/total colectomy, Hartmann’s procedure and proctocolectomy.

© 2018 The Authors.

www.bjsopen.com
percentage of stage III colorectal cancers has not increased proportionately, and at 20 years the Surveillance, Epidemiology, and End Results (SEER) data showed no correlation between the proportion of positive lymph nodes and LNY despite an increase in LNY, suggesting that stage migration alone may not account for improved survival in patients with colorectal cancer.

The prognostic significance of low LNY (less than 12) is debatable in locally advanced rectal cancer treated with neoadjuvant therapy, as LNY is known to be reduced in this setting. Several studies have found no survival difference between low and high LNY groups in this setting. Some studies have suggested that lymph node ratio (LNR) should be used for prognostication rather than LNY in stage III colorectal cancer, as it is more representative of tumour burden.

This study aimed to examine the correlation between clinical variables and LNY, and to examine the prognostic significance of LNY and LNR in stage 0 (complete pathological response, pCR) and stage I–III colorectal cancer.

Table 3: Multivariable analysis of factors affecting lymph node yield

| Variable                        | β coefficient | Hazard ratio |
|---------------------------------|---------------|--------------|
| Age (continuous)                | -0.09 (−0.13, −0.05) |              |
| Rectal cancer                   |               |              |
| No                              | 1.00 (reference) |              |
| Yes                             | -1.01 (−2.03, 0.02) |              |
| Surgical entry                  |               |              |
| Laparoscopic                    | 1.00 (reference) |              |
| Open                            | 1.32 (−2.39, −0.24) |              |
| Hybrid                          | -1.04 (−2.62, 0.53) |              |
| Conversion                      | -0.90 (−2.27, 0.46) |              |
| Robotic                         | -3.74 (−5.90, −1.58) |              |
| Elective surgery                |               |              |
| No                              | 1.00 (reference) |              |
| Yes                             | -3.44 (−5.14, −1.73) |              |
| pAJCC                           |               |              |
| 0                               | 1.00 (reference) |              |
| I                               | 2.44 (0.24, 4.63) |              |
| II                              | 4.80 (2.59, 7.01) |              |
| III                             | 5.33 (3.10, 7.57) |              |
| Rectal cancer with neoadjuvant therapy |   |          |
| pAJCC                           |               |              |
| 0                               | 1.00 (reference) |              |
| I                               | 2.07 (−1.07, 5.21) |              |
| II                              | 2.14 (−0.49, 4.77) |              |
| III                             | 3.64 (0.88, 6.41) |              |
| Neoadjuvant therapy type        |               |              |
| Long-course CRT                 | 1.00 (reference) |              |
| Short-course radiotherapy       | 7.03 (3.78, 10.27) |              |

Values in parentheses are 95 per cent confidence intervals. *Linear regression using lymph node yield (less than 12 or 12 or more) as a dichotomous variable. pAJCC, pathological stage according to the AJCC; CRT, chemoradiotherapy.

Table 4: Univariable and multivariable analysis of factors affecting disease-free survival from colorectal cancer

| Variable                        | Hazard ratio |
|---------------------------------|--------------|
| Univariable analysis            |              |
| LNY ≥ 12                        | 0.80 (0.55, 1.17) |
| Multivariable analysis          |              |
| LNY < 12                        | 1.00 (reference) |
| ≥ 12                            | 0.91 (0.41, 2.07) |
| pAJCC                           |              |
| 0                               | No disease progression |
| I                               | 1.00 (reference) |
| II                              | 3.89 (2.05, 7.37) |
| III                             | 7.49 (4.05, 13.85) |

Values in parentheses are 95 per cent confidence intervals. Predictor variables were included in analyses if significant at the 5 per cent level. LNY, lymph node yield; pAJCC, pathological stage according to the AJCC.

Methods

An observational study was performed using the Cabrini Monash University colorectal neoplasia database of consecutive patients treated for stage I–III colorectal adenocarcinoma under the care of 11 colorectal surgeons at Cabrini, Avenue and Alfred hospitals (Melbourne, Victoria, Australia) between January 2010 and March 2016. These three hospitals treat a mixture of private and public patients, and are broadly representative of all socioeconomic groups within the city of Melbourne. Ethical approval for this study was obtained from Cabrini Human Research Ethics Committee (reference 04-21-03-16).

Oncological resection involved en bloc resection of tumour with clear margins and high ligation of vascular pedicles, which ensured adequate lymphadenectomy. Neoadjuvant therapy, either long-course chemoradiotherapy (nCRT) or short-course radiotherapy, was routinely offered to patients with locally advanced rectal cancer (T3–4 or node-positive disease). Patients with pCR after neoadjuvant therapy were included in the study. pCR was defined by the absence of residual tumour cells in the surgical specimen, as described previously. Patients who presented with distant metastasis and/or synchronous colorectal cancer were excluded.

Management decisions were based on multidisciplinary team meetings held before surgery. Resected specimens were examined by the pathology department at the hospital in which the resection took place (the small number of specimens from Avenue Hospital were outsourced to a pathology service). Tumours were staged according to AJCC guidelines (7th edition). Pathological examination of lymph nodes in resected specimens relied on manual dissection by the pathologists. Low LNY was defined...
as fewer than 12 nodes in the resected specimen. If the initial LNY was less than 12, a fat clearance technique using Carnoy’s solution was performed routinely in two of the three sites to increase the yield. LNR was defined as the ratio of metastatic lymph nodes to the total number of lymph nodes examined. LNR was classified into four tiers based on rectal cancer data published by Danish Colorectal Cancer Group5: LNR 1, less than 0·08; LNR 2, 0·08 to less than 0·25; LNR 3, 0·25 to less than 0·50; LNR 4, 0·5–1·0.

All patients had routine follow-up every 3–6 months for the first 2 years with serial measurement of carcinoembryonic antigen. CT of the chest, abdomen and pelvis was performed annually in addition to colonoscopy as deemed clinically appropriate. After 2 years, follow-up was usually annual, with CT, estimation of blood tumour markers and colonoscopy for metachronous disease performed at the discretion of the treating surgeon and in line with national guidelines. In data analyses, follow-up was defined as the

---

Fig. 1 Kaplan–Meier analysis of disease-free survival in patients with colonic cancer according to high (12 or more) and low (less than 12) lymph node yield (LNY): a stage I, b stage II, c stage III. a P = 0·355, b P = 0·751, c P = 0·002 (log rank test)

Fig. 2 Kaplan–Meier analysis of disease-free survival in patients with rectal cancer according to high (12 or more) and low (less than 12) lymph node yield (LNY): a stage I, b stage II, c stage III. a P = 0·493, b P = 0·912, c P = 0·058 (log rank test)
Lymph node yield and ratio for outcome prediction in colorectal cancer

Fig. 3 Kaplan–Meier analysis of overall survival in patients with colonic cancer according to high (12 or more) and low (less than 12) lymph node yield (LNY): a stage I, b stage II, c stage III. a $P = 0.697$, b $P = 0.881$, c $P = 0.004$ (log rank test)

Fig. 4 Kaplan–Meier analysis of overall survival in patients with rectal cancer according to high (12 or more) and low (less than 12) lymph node yield (LNY): a stage I, b stage II, c stage III. a $P = 0.448$, b $P = 0.469$, c $P = 0.951$ (log rank test)

time from the date of primary surgery to a patient event, such as disease recurrence or death. There was no minimum duration of follow-up. Follow-up information was derived from the colorectal neoplasia database and patient hospital records. After surgery for the primary tumour, patients who developed local recurrence or metastasis were no longer considered disease-free for statistical analysis. Patients who died at any time, for any reason, after surgery were counted as deaths in overall survival analysis.

Statistical analysis

Data analysis was performed using Stata® 14 (StataCorp, College Station, Texas, USA). Linear regression (ordinary least squares) was used to analyse the association of LNY and LNR with clinical variables (histological grade, overall stage, tumour site and use of neoadjuvant therapy if rectal cancer). The effects of LNY and LNR on disease-free (DFS) and overall (OS) survival...
were investigated using survival analysis techniques (Cox regression, Kaplan–Meier survival analysis and log rank tests). Independent prognostic factors were identified in both univariable and multivariable analyses (Cox regression). χ² tests were used in additional analyses between groups. The significance level was set at 5 per cent, and terms were included in the models when the P value was below this level. Robust standard error estimates were obtained to account for the lack of independence between observations for patients with more than one procedure. P < 0·050 (two-tailed) was considered statistically significant.

### Results

A total of 1573 patients fulfilled the selection criteria. Some 1585 resections were performed with curative intent (colonic cancer, 1015 (64·0 per cent); rectal cancer, 570 (36·0 per cent)), and 12 were excluded (local recurrence, 2; metachronous colorectal cancer, 10). Of the 1585 resections, 1163 (73·4 per cent) were treated at Cabrini Hospital, 401 (25·3 per cent) at Alfred Hospital and 21 (1·3 per cent) at Avenue Hospital. The median duration of follow-up was 27·1 (range 0·1–71) months. The median LNY was 16 (range 0–86), and 372 (23·5 per cent) of all resections had an LNY below 12. Median age was 71 (range 22–100) years. Of the 570 patients with rectal cancer, 241 (42·3 per cent) received neoadjuvant therapy; 211 (87·6 per cent) received long-course nCRT and 30 (12·4 per cent) had short-course radiotherapy. Patient characteristics and clinicopathological features are summarized in Table 1.

### Role of lymph node yield

In the univariable linear regression model several factors were associated with LNY (Table 2). LNY was lower in rectal cancer with increasing age and in patients undergoing long-course (versus short-course) neoadjuvant therapy, for open, hybrid and robotic surgical (versus laparoscopic) approaches, for undifferentiated cancers (versus well differentiated) and for lower rectal (versus upper) and left-sided (versus right-sided) tumours. Conversely, LNY was higher in urgent and emergency (versus elective) surgery, in hepatic flexure (versus caecal) tumours, in poorly differentiated (versus well differentiated) cancers, in stage I–III (versus stage 0) tumours, and in patients with mismatch repair protein deficiency. There was no significant association between LNY and sex, BMI or conversion of surgical entry.

There were no significant differences between patients with low (below 12) or high (12 or above) LNY for a number of measured variables, including ASA grade (P = 0·978, χ² test) and positive circumferential resection margin (P = 0·939, χ² test). There were also no differences between surgeon (P = 0·104, χ² test) or hospital site (P = 0·317, χ² test). LNY was lower in patients with lymphovascular invasion (P = 0·017, χ² test).

In multivariable analysis using linear regression, LNY below 12 was associated with increasing age, open surgery, robotic surgery (performed by 5 surgeons in 2012–2016) and elective surgery (Table 3). High LNY (12 or above) was associated with stage I–III versus stage 0 tumours. Patients with rectal cancer who had received neoadjuvant therapy showed a higher LNY for stage III pAJCC cancers alone and when in receipt of short-course radiotherapy (Table 3).

Of the 1320 (83·9 per cent) of 1573 patients with colorectal cancer for whom follow-up data were available, 130 (9·8 per cent) had disease progression within 5 years. Univariable survival analysis showed no statistical difference in DFS between low LNY (less than 12) and high LNY (12 or more) (Table 4). Multivariable analysis, adjusted for pathological stage, showed a lower risk of disease progression...
when 12 or more lymph nodes were collected (Table 4). A higher risk of progression was also evident for stage II or III compared with stage I tumours. No patient with stage 0 (pCR) progressed.

After identifying an association between rectal cancer and low LNY (below 12), colonic and rectal cancer subdivisions were analysed further. DFS for colonic cancer was worse only for stage III tumours when data were stratified by low versus high LNY: stage I, $P = 0.355$; stage II, $P = 0.751$; stage III, $P = 0.002$ (log rank test) (Fig. 1). In contrast, there were no differences in DFS for rectal cancer when different stages were compared: stage I, $P = 0.493$; stage II, $P = 0.912$; stage III, $P = 0.058$ (log rank test) (Fig. 2). OS for colonic cancer was worse only for stage III tumours when data were stratified by low LNY versus high LNY: stage I, $P = 0.697$; stage II, $P = 0.881$; stage III, $P = 0.004$ (log rank test) (Fig. 3). There were no differences in OS for rectal cancer when different stages were compared: stage I, $P = 0.448$; stage II, $P = 0.469$; stage III, $P = 0.951$ (log rank test) (Fig. 4).

When the 241 patients who had rectal cancer and underwent nCRT were examined, there was no association between LNY and DFS (hazard ratio (HR) 0.97, 95 per cent c.i. 0.91 to 1.03) or OS (HR 1.02, 0.97 to 1.07).

### Table 7 Multivariable analysis of the effect of lymph node ratio quartile on overall survival in colorectal cancer

| LNRQ                  | Hazard ratio |
|-----------------------|--------------|
| 0 to < 0.0825         | 1.00 (reference) |
| 0.0825 to < 0.25      | 1.64 (1.03, 2.62) |
| 0.25 to < 0.5         | 2.26 (1.22, 4.17) |
| 0.5–1                 | 4.59 (2.27, 9.28) |

Values in parentheses are 95 per cent confidence intervals. LNRQ, lymph node ratio quartile.

### Role of lymph node ratio

Higher LNR was associated with poorer DFS in multivariable analyses of colorectal cancer (Table 5). Risk of disease progression increased with increasing LNR quartile (0.25 and above).

When colonic and rectal cancer were considered separately, LNR was an independent predictor of DFS in stage III colonic cancer, with patients having poorer DFS with LNRs greater than 0.25 (Table 6). LNR of 0.5 or above was also a risk factor for patients with stage III rectal cancer (Table 6 and Fig. 5b).

In the cohort of 1320 patients with colorectal cancer for whom follow-up data were available (83.9 per cent), 128 (9.7 per cent) died within 5 years of surgery.
Fig. 6 Kaplan–Meier analysis of overall survival in patients with stage III a colonic and b rectal cancer according to lymph node ratio quartile: Q1, 0 to less than 0.0825; Q2, 0.0825 to less than 0.25; Q3, 0.25 to less than 0.5; Q4, 0.5–1. a P = 0.007, b P = 0.391 (log rank test)

Table 8 Univariable analysis of the effect of lymph node ratio quartile on overall survival in stage III cancers

| LNRQ         | Hazard ratio   |
|--------------|----------------|
| Colonic cancer stage III only |                  |
| 0 to < 0.0825 | 1.00 (reference) |
| 0.0825 to < 0.25 | 4.44 (1.31, 15.08) |
| 0.25 to < 0.5  | 5.90 (1.62, 21.49) |
| 0.5–1         | 12.00 (2.92, 49.29) |
| Rectal cancer stage III only |                  |
| 0 to < 0.0825 | 1.00 (reference) |
| 0.0825 to < 0.25 | 1.29 (0.30, 5.51) |
| 0.25 to < 0.5  | 2.70 (0.45, 16.20) |
| 0.5–1         | 2.78 (0.55, 14.09) |

Values in parentheses are 95 per cent confidence intervals. LNRQ, lymph node ratio quartile.

Although univariable analysis showed no difference in OS according to the number of lymph nodes harvested (HR 0.99, 95 per cent c.i. 0.97 to 1.02; P = 0.620) or with an LNY of 12 or more (HR 0.91, 0.62 to 1.34; P = 0.646), a higher LNR (as a continuous variable) was associated with lower OS (HR 6.99, 3.31 to 14.78). In multivariable analysis, poorer OS was associated with higher LNR quartile (Table 7).

In the 241 patients with rectal cancer who had nCRT, poorer DFS was observed in patients with an LNR of 0.5–1 than in those with the lowest LNR (0–0.0825) (HR 11.24, 95 per cent c.i. 3.48 to 36.35). Compared with the reference group (LNR 0–0.0825), there was no association between LNR and OS in patients with an LNR of 0.0825 to less than 0.25 (HR 0.44, 0.06 to 3.36) or those with an LNR of 0.25 to less than 0.5 (HR 1.63, 0.21 to 12.45). When data were subdivided into colonic and rectal cancers, an LNR below 0.25 was associated with decreased OS in stage III colonic cancer (P = 0.007) (Fig. 6a and Table 8). LNR was not a predictor of OS in stage III rectal cancer (Table 8 and Fig. 6b).

Discussion

LNY is an important prognostic factor in patients with stage II–III colorectal cancer, but evidence for stage I colorectal cancer is unclear. Although there are studies reporting differences in survival between low and high LNY in patients with Dukes’ A/stage I colorectal cancer, some indicate that LNY alone has no effect on survival outcome. The present study highlights that a substantial number of patients with stage I and II colorectal cancer have a low LNY. Nonetheless, both DFS and OS...
in stage I and II colonic and rectal cancers in the present cohort were excellent and not influenced by LNY. Low LNY in stage III colon cancer did, however, result in poorer DFS and OS. Low LNY had no effect on DFS or OS for rectal cancer.

LNR is generally considered more reliable as a prognostic tool in stage III colorectal cancer. A systematic review and meta-analysis involving 33,984 patients with stage III colorectal cancer described numerous different cut-off LNR values. The authors concluded LNR was a more reliable prognostic factor than total number of positive nodes. In the present study, a higher LNR resulted in worse DFS and OS in colorectal cancer. In addition, a high LNR correlated with a poorer DFS for both stage III colonic and rectal cancers. In stage III colonic cancer a high LNR also correlated with a poorer OS, whereas there was no correlation between LNR and OS in stage III rectal cancer. A high LNR in rectal cancer following neoadjuvant therapy resulted in worse DFS.

Neoadjuvant therapy is the current standard of care for locally advanced rectal cancer (T3–4 or node-positive disease). A reduction in LNY secondary to radiotherapy is well recognized and the prognostic role of LNY in this setting is debatable. Miller and colleagues examined seven cohort studies and found a significant reduction in mean LNY in the nCRT group compared with that in patients who did not undergo nCRT (range 7–53 per cent). Despite some studies showing that low LNY in rectal cancer treated with neoadjuvant therapy may be associated with poorer survival, there is emerging evidence that low LNY in this clinical setting may not necessarily confer a poorer prognosis. A systematic review of 11 studies showed that although preoperative radiotherapy for locally advanced rectal cancer was associated with a lower LNY, most studies did not identify any adverse outcome in the low LNY group. This is consistent with the present findings in the subgroup of patients with locally advanced rectal cancer treated with nCRT.

In the present study, 23.5 per cent of all colorectal cancer resections were below the current benchmark of a minimum harvest of 12 lymph nodes; this is comparable to contemporary data from specialist centres, but lower than that from other population-based studies. The majority of the variation in reported LNY is likely to be due to non-modifiable patient-specific factors, including tumour characteristics. Factors such as older age, early tumour stage, type of operation (left-sided/rectal operation compared with right-sided) and use of neoadjuvant therapy in locally advanced rectal cancer have all been shown to be associated with low LNY. This was reflected in the present study, where lower LNY rates were associated with rectal cancer, elective surgery, stage 0 and I tumours, older patient age, left-sided surgery and neoadjuvant treatment. Studies have shown that operations performed by colorectal specialists in high-volume centres are more likely to have a higher LNY than those performed by non-specialists. It is possible that both surgeon and pathologist factors contributed to the LNY observed in the present study. In addition, fat clearance techniques can enhance lymph node assessment.

The present study has a number of limitations. Its observational nature is mitigated by the existence of a specific database for the collection of patient information. Although it is possible that there may have been differences in the way resection specimens were processed, the pathology departments followed the same AJCC guidelines. There was no statistical difference between the three hospitals in terms of LNY. A proportion of patients were lost to follow-up – around 16 per cent over the study interval of 6 years. It is not known whether DFS and OS data would be different with full patient follow-up (1573 in contrast to the 1320 patients for whom follow-up data were available.

The principle of oncological resection is to create clear margins. Together with high ligation of the vascular pedicle, adequate lymph nodes can be harvested in the corresponding drainage basin. This allows accurate pathological staging of colorectal cancer that guides adjuvant chemotherapy. Nonetheless, despite following this principle, low LNY can be associated with earlier-stage colorectal cancer as demonstrated in the present study. Low LNY in these clinical settings did not confer a poorer prognosis provided an adequate oncological resection and thorough examination of the surgical specimen had been performed.

These results support the use of LNR as a prognostic tool in stage III colorectal cancer to inform surveillance and treatment discussions (for instance with regard to adjuvant chemotherapy) following primary surgery. In addition, the use of LNR rather than LNY seems more logical in patients with rectal cancer treated with neoadjuvant therapy, given the tendency for a significant reduction in LNY.

Acknowledgements

C.H.A.L. and S.W. contributed equally to this study.

The authors thank colorectal surgeons S. Bell, M. Chin, P. Carne, K. C. Farmer, A. Polglase, P. Ranchod, P. Simpson, S. Skinner, R. Wale and S. Warrier for contributing their patients to this study. They also thank Let’s Beat Bowel Cancer (www.letsbeatbowelcancer.com), a benevolent fundraising and public awareness organization, for financial support during this project.
Disclosure: The authors declare no conflict of interest.

References

1 American Joint Committee on Cancer. AJCC Cancer Staging Manual (7th edn). Springer: New York, 2010.

2 Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A et al.; ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi64–vii2.

3 Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–2516.

4 Royal College of Pathologists of Australasia (RCPA). Colorectal Cancer Structured Reporting Protocol (2nd edn). RCPA, Surry Hills, 2012.

5 Lykke J, Jess P, Roikjaer O; Danish Colorectal Cancer Group. The prognostic value of lymph node ratio in a national cohort of rectal cancer patients. Eur J Surg Oncol 2016; 42: 504–512.

6 Nathan H, Shore AD, Anders RA, Wick EC, Gearhart SL, Pawlik TM. Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital? J Gastrointest Surg 2011; 15: 471–479.

7 Ahmadi O, Stringer MD, Black MA, McCall JL. Clinico-pathological factors influencing lymph node yield in colorectal cancer and impact on survival: analysis of New Zealand cancer registry data. J Surg Oncol 2015; 111: 451–458.

8 Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB III et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19: 157–163.

9 Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 2006; 93: 439–445.

10 Norwood MG, Sutton AJ, West K, Sharpe DP, Hemingway D, Kelly MJ. Lymph node retrieval in colorectal cancer resection specimens: national standards are achievable, and low numbers are associated with reduced survival. Colorectal Dis 2010; 12: 304–309.

11 Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433–441.

12 Namm J, Ng M, Roy-Chowdhury S, Morgan JW, Lum SS, Wong JH. Quantitating the impact of stage migration on staging accuracy in colorectal cancer. J Am Coll Surg 2008; 207: 882–887.

13 Budde CN, Tsikitis VL, Deveney KE, Diggs BS, Lu KC, Herzog DO. Increasing the number of lymph nodes examined after colectomy does not improve colon cancer staging. J Am Coll Surg 2014; 218: 1004–1011.

14 Habr-Gama A, Perez RO, Proscourshim I, Rawet V, Pereira DD, Sousa AH et al. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon Rectum 2008; 51: 277–283.

15 Tsai HL, Huang CW, Yeh YS, Ma CJ, Chen CW, Lu CY et al. Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I–III colorectal cancer patients: a retrospective single institution cohort study of 1167 consecutive patients. BMC Surg 2016; 16: 17.

16 Leonard D, Remue C, Abbes Orahni N, van Maanen A, Danse E, Dragean A et al. Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre. Colorectal Dis 2016; 18: O175–O184.

17 Lykke J, Jess P, Roikjaer O; Danish Colorectal Cancer Group. A minimum yield of twelve lymph nodes in rectal cancer remains valid in the era of neo-adjuvant treatment: results from a national cohort study. Int J Colorectal Dis 2015; 30: 347–351.

18 Miller ED, Robb BW, Cummings OW, Johnstone PA. The effects of preoperative chemoradiotherapy on lymph node sampling in rectal cancer. Dis Colon Rectum 2012; 55: 1002–1007.

19 Ha YH, Jeong SY, Lim SB, Choi HS, Hong YS, Chang HJ et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 2010; 252: 336–340.

20 Doll D, Gertler R, Maak M, Friederichs J, Becker K, Geinitz E, Dragean A et al. Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance. World J Surg 2009; 33: 340–347.

21 Persiani R, Biondi A, Gambacorta MA, Bertucci Zoccali M, Vecchio FM, Tufo A et al. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg 2014; 101: 133–142.

22 de Campos-Lobato LF, Stocchi L, de Sousa JB, Buta M, Lavery IC, Fazio VW et al. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! Ann Surg Oncol 2013; 20: 3398–3406.

23 Moug SJ, Saldanha JD, McGregor JR, Balsitis M, Diament RH. Positive lymph node retrieval ratio optimises patient staging in colorectal cancer. Br J Cancer 2009; 100: 1530–1533.

24 Noura S, Ohue M, Kano S, Shingai T, Yamada T, Miyashiro I et al. Impact of metastatic lymph node ratio in node-positive colorectal cancer. World J Gastrointest Surg 2010; 2: 70–77.

25 Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review. Ann Surg Oncol 2010; 17: 2847–2855.

26 McMurrick PJ, Oliva K, Carne P, Reid G, Polglase A, Bell S et al. The first 1000 patients on an internet-based colorectal neoplasia database across private and public medicine in
Lymph node yield and ratio for outcome prediction in colorectal cancer

Australia: development of a binational model for the Colorectal Surgical Society of Australia and New Zealand. *Dis Colon Rectum* 2014; 57: 167–173.

27 Wilkins S, Haydon A, Porter I, Oliva K, Staples M, Carne P et al. Complete pathological response after neoadjuvant long-course chemoradiotherapy for rectal cancer and its relationship to the degree of T3 mesorectal invasion. *Dis Colon Rectum* 2016; 59: 361–368.

28 Sarli L, Bader G, Iusco D, Salvemini C, Mauro DD, Mazzeo A et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. *Eur J Cancer* 2005; 41: 272–279.

29 Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol* 2003; 21: 2912–2919.

30 Vather R, Sammour T, Kahokehr A, Connolly AB, Hill AG. Lymph node evaluation and long-term survival in stage II and stage III colon cancer: a national study. *Ann Surg Oncol* 2009; 16: 585–593.

31 Stocchi L, Fazio VW, Lavery I, Hammel J. Individual surgeon, pathologist, and other factors affecting lymph node harvest in stage II colon carcinoma. Is a minimum of 12 examined lymph nodes sufficient? *Ann Surg Oncol* 2011; 18: 405–412.

32 George S, Primrose J, Talbot R, Smith J, Mullee M, Bailey D et al.; Wessex Colorectal Cancer Audit Working Group. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. *Br J Cancer* 2006; 95: 841–847.

33 Bläker H, Hildebrandt B, Riess H, von Winterfeld M, Ingold-Heppner B, Roth W et al. Lymph node count and prognosis in colorectal cancer: the influence of examination quality. *Int J Cancer* 2015; 136: 1957–1966.

34 Wang J, Hassett JM, Dayton MT, Kulaylat MN. Lymph node ratio: role in the staging of node-positive colon cancer. *Ann Surg Oncol* 2008; 15: 1600–1608.

35 Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW et al. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. *Cancer* 2011; 117: 3713–3722.

36 Park IJ, Yu CS, Lim SB, Yoon YS, Kim CW, Kim TW et al. Prognostic implications of the number of retrieved lymph nodes of patients with rectal cancer treated with preoperative chemoradiotherapy. *J Gastrointest Surg* 2014; 18: 1845–1851.

37 Kim HJ, Jo JS, Lee SY, Kim CH, Kim YJ, Kim HR. Low lymph node retrieval after preoperative chemoradiation for rectal cancer is associated with improved prognosis in patients with a good tumor response. *Ann Surg Oncol* 2015; 22: 2075–2081.

38 Awad GE, Tou SI, Rieger NA. Prognostic significance of lymph node yield after long-course preoperative radiotherapy in patients with rectal cancer: a systematic review. *Colorectal Dis* 2013; 15: 394–403.

39 Dent OF, Newland RC, Chan C, Bokey L, Chapuis PH. Trends in pathology and long-term outcomes after resection of colorectal cancer: 1971-2013. *ANZ J Surg* 2017; 87: 34–38.

40 Steele SR, Chen SL, Stojadinovic A, Nissan A, Zhu K, Peoples GE et al. The impact of age on quality measure adherence in colon cancer. *J Am Coll Surg* 2011; 213: 95–103; discussion 104–105.

41 Lykke J, Roikjaer O, Jess P; Danish Colorectal Cancer Group. Tumour stage and preoperative chemoradiotherapy influence the lymph node yield in stages I–III rectal cancer: results from a prospective nationwide cohort study. *Colorectal Dis* 2014; 16: O144–O149.

42 Tekkis PP, Smith JJ, Heriot AG, Darzi AW, Thompson MR, Stamatakis JD; Association of Coloproctology of Great Britain and Ireland. A national study on lymph node retrieval in resectional surgery for colorectal cancer. *Dis Colon Rectum* 2006; 49: 1673–1683.

43 Biliomory KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER et al. Impact of tumor location on nodal evaluation for colon cancer. *Dis Colon Rectum* 2008; 51: 154–161.

44 Hsu CW, Lin CH, Wang JH, Wang IH, Ou WC, King TM. Factors that influence 12 or more harvested lymph nodes in early-stage colorectal cancer. *World J Surg* 2009; 33: 333–339.

45 Jeganathan AN, Shanmugan S, Bleier JJ, Hall GM, Paulson EC. Colorectal specialization increases lymph node yield: evidence from a national database. *Ann Surg Oncol* 2016; 23: 2258–2265.

46 Scott KW, Grace RH, Gibbons P. Five-year follow-up study of the fat clearance technique in colorectal carcinoma. *Dis Colon Rectum* 1994; 37: 126–128.

47 Duldulao M, Booth C, Denham L, Choi A, Friedman G, Kazanjian K. Alcohol fat clearing increases lymph node yield after surgery for colorectal cancer. *Am Surg* 2014; 80: 1054–1058.